In vivo and non-invasive measurement of cytokine release in a mechanistic model of acute skin barrier disruption

In vivo and non-invasive measurement of cytokine release in a mechanistic model of acute skin barrier disruption - Cytokine measurement following skin barrier disruption

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON42792

Enrollment

Registered

2015-08-04

Start date

2015-09-21

Completion date

Unknown

Last updated

2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cytokines inflammatory molecules

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Age between 18 and 65 years; Must be willing to give a written informed consent; Must have skin type II or III (Fitzpatrick scale)

Exclusion criteria

Exclusion criteria: Pregnancy or lactation; Atopic predisposition (i.e. history of allergic rhinitis or allergic conjunctivitis, atopic or contact dermatitis, hay fever, asthma); Any skin disease, including possible lesions found during screening; Skin types I, IV, V, VI; Use of immunosuppressive drugs (NSAIDs, biological, topical or systemic corticosteroids)

Design outcomes

Primary

Measure	Time frame
The main study eindpoints are the levels of cytokines at baseline and at different time points following acute disruption of the skin barrier by means of tape stripping.	—

Countries

Netherlands

Outcome results